RVL Pharmaceuticals plc (NASDAQ: RVLP) to Attend H.C. Wainwright 25th Annual Global Investment Conference and Discuss UPNEEQ(R) for Treating Acquired Blepharoptosis
- RVL Pharmaceuticals’ CEO Brian Markison and COO JD Schaub will participate in a fireside chat and 1-on-1 investor meetings on Tuesday, September 12, 2023, during this year’s H.C. Wainwright Annual Global Investment Conference in New York City
- The company will discuss UPNEEQ(R) and its use as the first non-surgical treatment option approved by the FDA for acquired blepharoptosis
- RVL Pharmaceuticals plans to continue marketing to medical aesthetics providers and will launch a direct-to-consumer campaign later this year
- The medical aesthetics market was valued at $13.9 billion in 2022 and is expected to reach $23.4 billion by 2027
RVL Pharmaceuticals (NASDAQ: RVLP), a specialty pharmaceutical company, recently announced that its CEO Brian Markison will be participating in a fireside chat and hosting 1-on-1 investor meetings during the H.C. Wainwright 25th Annual Global Investment Conference in New York City on Tuesday, September 12, 2023. Mr. Markison will be discussing the company and its commercialization of UPNEEQ(R) (oxymetazoline hydrochloride ophthalmic solution), 0.1%, which is available by prescription for the treatment of acquired blepharoptosis, also known as ptosis or low-lying eyelid(s), in adults (https://nnw.fm/lnr5O ).
UPNEEQ(R) is the first non-surgical treatment option approved by the U.S. Food and Drug Administration (“FDA”) for acquired blepharoptosis. The company obtained the necessary FDA approvals in July 2020 – launching UPNEEQ(R) in September 2020 to a limited number of eye care professionals. The company began expanding its commercial operations in 2021 to include ophthalmology, optometry, and oculoplastic specialties. In 2022, UPNEEQ(R) was launched into the U.S. medical aesthetics market.
In 2022, the global medical aesthetics market had an estimated value of $13.9 billion. By 2027, the estimated value is expected to reach $23.4 billion, representing a compound annual growth rate (“CAGR”) of 11%. The market’s projected growth is attributed to the rising preference for minimally invasive aesthetic procedures over traditional surgical options (https://nnw.fm/4UMsy ).
UPNEEQ(R), the first and only FDA-approved eye drop for low-lying eyelids, fits into the non-invasive medical aesthetics category. With a single drop per day, clinical trials showed an average of one-millimeter lift to the upper eyelid, improving appearance and the superior visual field in patients with a functional deficit. Testing also showed that UPNEEQ(R) was well tolerated by participants and is safe; side effects were similar to those experienced in the placebo group.
RVL Pharmaceuticals believes that the growth in the medical aesthetics and eye care markets will be driven by an aging population and an increased life expectancy, resulting in more consumers who desire improved appearance and well-being over a longer period. The company also anticipates other contributing factors that include the growing awareness, utilization, and improved accessibility of treatments due to an increase in physicians offering eye care and medical aesthetics services.
Low-lying lids can affect adults of all ages. A survey conducted by eye care providers and medical aesthetics specialists revealed they believe that approximately half of the adult patients visiting their practices are affected by drooping or low-lying eyelids. RVL Pharmaceuticals estimates that approximately 60% of adult women self-identify as having some degree of ptosis, indicating that they are bothered by the position of their eyelids.
UPNEEQ(R) customers include optometrists, ophthalmologists, oculoplastic surgeons, facial plastic surgeons, dermatologists, and a broad range of practitioners qualified to diagnose and treat acquired blepharoptosis in adults. Patients can purchase UPNEEQ(R) directly from eye care, medical aesthetic professionals, or RVL Pharmaceuticals’ wholly owned pharmacy, RVL Pharmacy LLC. To support patients, RVL Pharmaceuticals launched the Elevate platform this year, which enables UPNEEQ(R) orders and subscription refills across HCP practices and RVL Pharmacy patients.
RVL Pharmaceuticals’ near-term focus is to continue the rollout of UPNEEQ(R) into the medical aesthetics market through its dedicated sales force. RVL is focused on raising patient and provider awareness of acquired ptosis through medical conferences, HCP and direct-to-consumer advertising, social media, and marketing partnerships.
The company’s fireside chat at the H.C. Wainwright 25th Annual Global Investment Conference will be webcast and available live and via replay from the RVL Pharmaceuticals website under the Investors & News section. The playback will be accessible for up to 90 days after the conference’s conclusion.
For more information, visit the company’s website at www.RVLPharma.com.
NOTE TO INVESTORS: The latest news and updates relating to RVLP are available in the company’s newsroom at https://nnw.fm/RVLP
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- RVL Pharmaceuticals’ CEO Brian Markison and COO JD Schaub will participate in a fireside chat and 1-on-1 investor meetings on Tuesday, September 12, 2023, during this year’s H.C. Wainwright Annual Global Investment Conference in New York City
- The company will discuss UPNEEQ(R) and its use as the first non-surgical treatment option approved by the FDA for acquired blepharoptosis
- RVL Pharmaceuticals plans to continue marketing to medical aesthetics providers and will launch a direct-to-consumer campaign later this year
- The medical aesthetics market was valued at $13.9 billion in 2022 and is expected to reach $23.4 billion by 2027
RVL Pharmaceuticals (NASDAQ: RVLP), a specialty pharmaceutical company, recently announced that its CEO Brian Markison will be participating in a fireside chat and hosting 1-on-1 investor meetings during the H.C. Wainwright 25th Annual Global Investment Conference in New York City on Tuesday, September 12, 2023. Mr. Markison will be discussing the company and its commercialization of UPNEEQ(R) (oxymetazoline hydrochloride ophthalmic solution), 0.1%, which is available by prescription for the treatment of acquired blepharoptosis, also known as ptosis or low-lying eyelid(s), in adults (https://nnw.fm/lnr5O ).
UPNEEQ(R) is the first non-surgical treatment option approved by the U.S. Food and Drug Administration (“FDA”) for acquired blepharoptosis. The company obtained the necessary FDA approvals in July 2020 – launching UPNEEQ(R) in September 2020 to a limited number of eye care professionals. The company began expanding its commercial operations in 2021 to include ophthalmology, optometry, and oculoplastic specialties. In 2022, UPNEEQ(R) was launched into the U.S. medical aesthetics market.
In 2022, the global medical aesthetics market had an estimated value of $13.9 billion. By 2027, the estimated value is expected to reach $23.4 billion, representing a compound annual growth rate (“CAGR”) of 11%. The market’s projected growth is attributed to the rising preference for minimally invasive aesthetic procedures over traditional surgical options (https://nnw.fm/4UMsy ).
UPNEEQ(R), the first and only FDA-approved eye drop for low-lying eyelids, fits into the non-invasive medical aesthetics category. With a single drop per day, clinical trials showed an average of one-millimeter lift to the upper eyelid, improving appearance and the superior visual field in patients with a functional deficit. Testing also showed that UPNEEQ(R) was well tolerated by participants and is safe; side effects were similar to those experienced in the placebo group.
RVL Pharmaceuticals believes that the growth in the medical aesthetics and eye care markets will be driven by an aging population and an increased life expectancy, resulting in more consumers who desire improved appearance and well-being over a longer period. The company also anticipates other contributing factors that include the growing awareness, utilization, and improved accessibility of treatments due to an increase in physicians offering eye care and medical aesthetics services.
Low-lying lids can affect adults of all ages. A survey conducted by eye care providers and medical aesthetics specialists revealed they believe that approximately half of the adult patients visiting their practices are affected by drooping or low-lying eyelids. RVL Pharmaceuticals estimates that approximately 60% of adult women self-identify as having some degree of ptosis, indicating that they are bothered by the position of their eyelids.
UPNEEQ(R) customers include optometrists, ophthalmologists, oculoplastic surgeons, facial plastic surgeons, dermatologists, and a broad range of practitioners qualified to diagnose and treat acquired blepharoptosis in adults. Patients can purchase UPNEEQ(R) directly from eye care, medical aesthetic professionals, or RVL Pharmaceuticals’ wholly owned pharmacy, RVL Pharmacy LLC. To support patients, RVL Pharmaceuticals launched the Elevate platform this year, which enables UPNEEQ(R) orders and subscription refills across HCP practices and RVL Pharmacy patients.
RVL Pharmaceuticals’ near-term focus is to continue the rollout of UPNEEQ(R) into the medical aesthetics market through its dedicated sales force. RVL is focused on raising patient and provider awareness of acquired ptosis through medical conferences, HCP and direct-to-consumer advertising, social media, and marketing partnerships.
The company’s fireside chat at the H.C. Wainwright 25th Annual Global Investment Conference will be webcast and available live and via replay from the RVL Pharmaceuticals website under the Investors & News section. The playback will be accessible for up to 90 days after the conference’s conclusion.
For more information, visit the company’s website at www.RVLPharma.com.
NOTE TO INVESTORS: The latest news and updates relating to RVLP are available in the company’s newsroom at https://nnw.fm/RVLP
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
